Could these groundbreaking therapies make conventional antibiotics a thing of the past?
Originally published on Labiotech.eu
With the rise of antimicrobial resistance across the globe, and with a dire lack of new antibiotics in the pipeline, more attention is going towards developing innovative treatments and technologies that kill superbugs in completely new ways. Here, we take a closer look at some of the most promising of these technologies emerging from the European biotech scene.
Humanity is in trouble. In 2014, then British Prime Minister David Cameron warned that the problem of antimicrobial resistance threatened to send us “back into the dark ages of medicine.” Since then, the problem has only become more urgent: superbugs are spreading fast, more patients are dying of superbug infections each year (with superbugs predicted to be a bigger killer than cancer by 2050), and the developmental pipeline of new antibiotics is worryingly dry. Just this month, pharmaceutical giant Novartis abandoned its research into new antibiotics, joining a long list of big pharma companies halting or scaling down their antibiotic research and development in recent years.
Clearly, radical new ideas are needed. Thankfully, the European biotech scene is rising to the occasion. So, what are these radical new ideas? And how do they work?